Cannabis for Cognitive Impairment

Recruiting in Palo Alto (17 mi)

Overseen by Dustin C Lee, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Johns Hopkins University

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.

Eligibility Criteria

This trial is for frequent and infrequent cannabis users to study how THC affects eye movements and attention. Participants must be able to consume THC and perform tasks that test their oculomotor function and sustained attention.

Inclusion Criteria

I am a healthy adult between 18 and 60 years old not seeking treatment.

Report infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline

Report frequent cannabis use defined as > 5 days per week for > 1 year with a positive THC urine toxicology at baseline

Exclusion Criteria

Meet DSM-V criteria for substance use disorders other than tobacco, cannabis, or caffeine

Test positive for drugs of abuse (other than cannabis) and/or breath alcohol test at study admission

Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity

Participant Groups

The study tests the effects of different doses of THC (0, 5mg, 30mg) on eye movement control and concentration in both regular and occasional cannabis users using a double-blind, placebo-controlled crossover design.

Group I: 5 mg THC Experimental Treatment 1 Intervention

Inhaled cannabis - 5 mg THC

Group II: 30 mg THC Experimental Treatment 1 Intervention

Inhaled cannabis - 30 mg THC

Group III: 0 mg THC Placebo Group 1 Intervention

Inhaled Cannabis - 0 mg THC

Cannabis is already approved in Canada, United States, European Union, Australia for the following indications:

🇨🇦 Approved in Canada as Cannabis for:

• Chronic pain
• Nausea and vomiting associated with chemotherapy
• Spasticity associated with multiple sclerosis

🇺🇸 Approved in United States as Cannabis for:

• Seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
• Nausea and vomiting associated with chemotherapy

🇪🇺 Approved in European Union as Cannabis for:

• Spasticity associated with multiple sclerosis
• Chronic pain

🇦🇺 Approved in Australia as Cannabis for:

• Chronic pain
• Nausea and vomiting associated with chemotherapy
• Spasticity associated with multiple sclerosis

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Johns Hopkins Behavioral Pharmacology Research Unit Baltimore, MD

Who Is Running the Clinical Trial?

Johns Hopkins University Lead Sponsor

National Institute on Drug Abuse (NIDA) Collaborator

References